Alpha-1-antitrypsin aerosolised augmentation abrogates neutrophil elastase-induced expression of cathepsin B and matrix metalloprotease 2 in vivo and in vitro

P Geraghty,1 M P Rogan,1 C M Greene,1 M L Brantly,2 S J O’Neill,1 C C Taggart,1 N G McElvaney1

ABSTRACT

Background: Neutrophil elastase (NE) activity is increased in lung diseases such as α1-antitrypsin (A1AT) deficiency and pneumonia. It has recently been shown to induce expression of cathepsin B and matrix metalloprotease 2 (MMP-2) in vitro and in a mouse model. It is postulated that increased cathepsin B and MMP-2 in acute and chronic lung diseases result from high levels of extracellular NE and that expression of these proteases could be inhibited by A1AT augmentation therapy.

Methods: Cathepsin and MMP activities were assessed in bronchoalveolar lavage (BAL) fluid from patients with A1AT deficiency, pneumonia and control subjects. Macrophages were exposed to BAL fluid rich in free NE from patients with pneumonia following pretreatment with A1AT. MMP-2, cathepsin B, secretory leucoprotease inhibitor (SLPI) and lactoferrin levels were determined in BAL fluid from A1AT-deficient patients before and after aerosolisation of A1AT.

Results: BAL fluid from both patients with pneumonia and those with A1AT deficiency containing free NE had increased cathepsin B and MMP-2 activities compared with BAL fluid from healthy volunteers. The addition of A1AT to BAL fluid from patients with pneumonia greatly reduced NE-induced cathepsin B and MMP-2 expression in macrophages in vitro. A1AT augmentation therapy to A1AT-deficient individuals also reduced cathepsin B and MMP-2 activity in BAL fluid in vivo. Furthermore, A1AT-deficient patients had higher levels of SLPI and lactoferrin after A1AT augmentation therapy.

Conclusion: These findings suggest a novel role for A1AT inhibition of NE-induced upregulation of MMP and cathepsin expression both in vitro and in vivo.

Raised levels of proteases are typically observed in acute and chronic lung diseases at sites of inflammation and infection. Proteases have a number of effects including tissue destruction, tissue remodelling and cleavage of soluble innate factors. We have previously shown that cathepsin B can cleave and inactivate key innate immunity proteins including lactoferrin1 and secretory leucoprotease inhibitor (SLPI).2 We have also recently described a novel hierarchy in protease regulation which showed that neutrophil elastase (NE) can induce the expression of cathepsin B and matrix metalloprotease 2 (MMP-2) in vitro and in a mouse model.3 MMPs and cathepsins have previously been found, together with NE, in conditions such as emphysema and cystic fibrosis.4 5 We postulated that increased extracellular NE activity in vivo may induce expression of both cathepsins and MMPs. These proteases are capable of significant tissue destruction and inflammation, both directly and indirectly by cleaving key innate anti-inflammatory and antimicrobial proteins. We hypothesised that NE-mediated upregulation of cathepsins and MMPs could be inhibited by α1-antitrypsin (A1AT), a naturally occurring inhibitor of NE. Reduced expression of these destructive proteases could have significant implications in reducing both lung inflammation and cleavage of innate immunity proteins.

In this study we demonstrate that NE upregulates cathepsin B and MMP-2 in vitro and in vivo in pneumonia and A1AT deficiency, and that this effect of NE can be prevented by A1AT. We show increased levels of the key innate immunity proteins lactoferrin and SLPI following A1AT aerosolised augmentation. Protease inhibitors are attractive therapeutic targets in many lung diseases. Inhibition of NE may provide a therapeutic target in conditions with increased cathepsin B and MMP-2 activities such A1AT deficiency, cystic fibrosis, chronic obstructive pulmonary disease and pneumonia. By inhibiting NE, it may be possible to abrogate not just the deleterious effects of this key serine protease, but also the effects of its cytoisyn and metalloprotease secretagogues—cathepsin B and MMP-2, respectively.

METHODS

Selection and description of patients with A1AT deficiency and pneumonia

An augmentation study of aerosolised A1AT in individuals with A1AT deficiency was carried out in the Department of Medicine, University of Florida, Gainesville using plasma purified A1AT produced by Aventis Behring (now ZLB Behring, King of Prussia, PA, USA). A1AT was interceded to dry powder by spray drying and packaged in unit dose blisters prior to delivery by a pulmonary delivery system (Nektar, formerly Inhaled Therapeutics, San Carlos, CA, USA). Briefly, a dry powder pulmonary device was used that disperses fine dry respirable powders in a reproducible fashion to the lung. The mass median aerodynamic particle size was 2 μm. This was a dose escalation study evaluating different doses of A1AT from 6 mg to 96 mg given once daily for 14 days.
After adequate sedation and analgesia, bronchoscopy and bronchoalveolar lavage (BAL) were performed with the subject in the supine position. The bronchoscope was wedged into the anterior segment of the right or left upper lobe. BAL was performed in each lobe with five sequential 20 ml aliquots of normal saline solution which were infused quickly with no dwell time between infusion and aspiration. BAL fluid from both lobes was combined and the percentage of the recovered volume was measured. Mucus was removed from the BAL fluid using two layers of sterilised cotton gauze. Cells were separated from the BAL fluid at 2000 rev/min for 15 min. The BAL fluid was then separated and stored at −70°C. The dosage was given once a day for 14 days. Patients were lavaged before entering the study and at a time point after the last aerosol. The pre-BAL day was day −13 or day −14 (ie, 13–14 days before the study) and the post-BAL day was 24 (4) h after the last dose (ie, day 15). For the purpose of this study we evaluated only those individuals with free NE in their BAL fluid before aerosolised augmentation therapy and those for whom we had access to post-aerosolised augmentation BAL samples (6 mg A1AT, n = 11). There was no selection bias before the data were analysed. BAL fluid was obtained according to standardised guidelines and as approved by the Beaumont Hospital and University of Florida Review Board committee. All subjects had a diagnosis of A1AT deficiency, PiZZ phenotype confirmed by nephelometry and isoelectric focusing.

BAL fluid was also obtained from nine patients (five men) with community acquired pneumonia of mean (SD) age 54.0 and 2.5% (v/v) Triton X-100 for 5 min, then incubated at 37°C overnight in the same buffer containing 0.5 M ZnCl and 2.5% (v/v) Triton X-100 for 5 min, then incubated at 37°C overnight in the same buffer containing 0.5 M ZnCl and 2.5% (v/v) Triton X-100 (Promega) in a 50 μl volume containing 100 pmol each of the following primers: 5′-ATG TGG CAG CTC TGG CCC T-3′ and 5′-TAC TGA TCG GTG GCA GGA ATT-3′ for cathepsin B; 5′-GCC CCC AAA ACC GAC AAC GA-3′ and 5′-TCC CAA GGT CCA TAG CTC ATC G-3′ for MMP-2; 5′-AAC TCT GCC AAA ACC GAC AAC GA-3′ and 5′-TCC CAA GGT CCA TAG CTC ATC G-3′ for MMP-2; 5′-AAC TCT GCC AAA ACC GAC AAC GA-3′ and 5′-TCC CAA GGT CCA TAG CTC ATC G-3′ for GAPDH. PCR products were quantified densitometrically at cycle numbers between 10 and 40 to determine the appropriate cycle number at which exponential amplification of products was occurring, and to identify the cycle number at which sufficient discrimination was possible to accurately quantify increases or decreases in gene expression. After a hot start the amplification profile was 32 cycles of 1 min denaturation at 94°C, 1 min annealing at 58°C and 1 min extension at 72°C. RT-PCR amplification of cathepsin B, MMP-2 and GAPDH generated products of 1004 bp, 525 bp and 211 bp, respectively. PCR products were commercially sequenced (MWG Biotech AG, Ebersberg, Germany) to verify gene identity. PCR products were resolved on a 1% agarose gel containing 0.5 μg/ml ethidium bromide (Sigma). The ratio of PCR fragment intensities of cathepsin B and MMP-2 relative to GAPDH was determined by densitometry.

**Presence of cathepsin B**

Cathepsin B activity was determined from either BAL fluid or medium taken from macrophage-like cells 24 h after stimulation with or without BAL in 100 μl of each sample using the substrate Z-Arg-Arg-AMC (0.1 mM). A cathepsin B inhibitor CA-074 (10 μg/ml) was used as a control for the specificity of the cathepsin B substrate. The reaction buffer used for cathepsin B activity estimation was 0.2 M sodium acetate, 2 mM EDTA, 1 mM DTT, 1 μM pepstatin and 2 mM Pefabloc, pH 5.5. The samples were incubated with substrate for 60 min at 37°C and fluorescence (substrate turnover) was determined by excitation at 355 nm and emission at 460 nm. The results were expressed as a change (delta) in fluorescence units (FU) over a 60 min period.

**Zymography**

Gelatin zymography was performed on either BAL fluid samples or medium collected from unstimulated or BAL fluid-stimulated cells. Samples were subjected to 7% SDS-polyacrylamide gel electrophoresis with a gel-containing gelatin (1 mg/ml). After electrophoresis, the gels were incubated in 50 mM Tris (pH 7.3), 5 mM CaCl₂, 1 μM ZnCl₂ and 2.5% (v/v) Triton X-100 for 50 min, washed in the same buffer without the Triton X-100 for 5 min, then incubated at 37°C overnight in the same buffer.
supplemented with 1% (v/v) Triton X-100. The gels were stained with 0.125% Coomassie Blue and washed with 10% acetic acid and 40% methanol in water. The presence of MMPs appears as transparent bands. Latent MMP-2 and active MMP-2 were observed at 72 and 66 kDa, respectively. Densitometry was carried out to compare the intensity of the MMP transparent bands.

Western blot analysis
BAL fluid from healthy controls and A1AT-deficient patients was investigated for the presence of cathepsin B. BAL fluid samples were separated by electrophoresis on 10% SDS-polyacrylamide gels and transferred to a nitrocellulose membrane (Sigma-Aldrich, Dublin, Ireland) which was probed using rabbit anti-cathepsin B antibody (Calbiochem, Nottingham, UK). Binding was detected using the appropriate horseradish peroxidase-conjugated secondary antibody and visualised by chemiluminescence (Pierce, Dublin, Ireland).

Densitometric analysis
Gels were analysed by densitometry and compared in a semiquantitative manner using the GeneGenius Gel Documentation and Analysis System (Cambridge, UK) and GeneSnap and GeneTools software. All expression values were verified by at least two independent experiments.

Statistical analysis
Data were analysed with the PRISM 3.0 software package (GraphPad, San Diego, CA, USA). The results are expressed as mean (SE) and were compared by t test. When more than two groups were being compared, an ANOVA test was used followed by a Tukey post hoc test. Differences were considered significant at p values <0.05.

RESULTS
BAL fluid characteristics
BAL fluid samples were collected from patients with A1AT deficiency, pneumonia and control subjects. Cytospin preparations were analysed to determine cell numbers/ml BAL fluid. The sample data for the A1AT-deficient patients are summarised in table 1. NE activity levels were reduced from 297.0 (325.4) to 0.00 nM/ELF following A1AT aerosolised augmentation therapy, but without reducing the percentage of neutrophils in the BAL fluid. Samples from pneumonia-infected lungs contained increased numbers of cells compared with controls (1.59×10^6 (8.3×10^5) cells/ml vs 3.89×10^5 (7.6×10^5) cells/ml, p<0.05). The macrophage:neutrophil ratio in the infected ELF was 5.3 compared with 4:1 in uninfected ELF. Pneumonia was characterised by a neutrophil influx with 5.5-fold more neutrophils at the infection site for control and infected subjects (8.4×10^4 (6.2×10^4) cells/ml and 4.7×10^5 (2.4×10^5) cells/ml, p<0.05).

Protease profile of BAL fluid
Cathepsin B and MMP-2 activities were measured in BAL fluid from individuals with A1AT deficiency and those with pneumonia. Increased cathepsin B activity was observed in BAL fluid from individuals with A1AT deficiency compared with BAL fluid from non-smoking healthy controls using the cathepsin substrate Z-Arg-Arg-AMC (fig 1A). Incubation of BAL fluid from A1AT-deficient subjects with the cathepsin B inhibitor CA-074 significantly reduced turnover of the substrate Z-Arg-Arg-AMC, indicating that cathepsin B is the primary cathepsin present in BAL fluid from individuals with A1AT deficiency (fig 1A, p<0.001 when all experimental groups were compared). This was further confirmed by Western blot analysis which demonstrated the presence of cathepsin B in BAL fluid from subjects with A1AT deficiency but not in BAL fluid from healthy control subjects (fig 1B).

Cathepsin B activity was higher in BAL fluid from patients with pneumonia than in BAL fluid from controls (fig 1A, p<0.001). Active forms of MMP-2 were present in BAL fluid from patients with A1AT deficiency and pneumonia but not in BAL fluid from control subjects (fig 1C).

Table 1 Clinical characteristics of the study population before and after aerosolised A1AT augmentation

<table>
<thead>
<tr>
<th>Criteria</th>
<th>Before aerosolised A1AT augmentation</th>
<th>After aerosolised A1AT augmentation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>52 (8)</td>
<td>52 (8)</td>
</tr>
<tr>
<td>M/F</td>
<td>60/40</td>
<td></td>
</tr>
<tr>
<td>FEV₁ (% predicted)</td>
<td>60.9 (12.4)</td>
<td>60.8 (10.5)</td>
</tr>
<tr>
<td>FEV₁/FVC (%)</td>
<td>53.7 (15.3)</td>
<td>52.0 (15.8)</td>
</tr>
<tr>
<td>Neutrophil counts (% of total cells)</td>
<td>27.0 (20.5)</td>
<td>31.3 (22.7)</td>
</tr>
<tr>
<td>NE activity (nM/ELF)</td>
<td>297.0 (325.4)</td>
<td>0.00*</td>
</tr>
</tbody>
</table>

Data are presented as median (SD). A1AT, α₁-antitrypsin; ELF, epithelial lining fluid; FEV₁, forced expiratory volume in 1 s; FVC, forced vital capacity; NE, neutrophil elastase.

* p<0.05 pre-treatment vs post-treatment.

Protease and antiprotease activity in patients with A1AT deficiency following aerosolised augmentation therapy
Cathepsin B and MMP-2 activity was measured in BAL fluid from patients with A1AT deficiency before and after A1AT
treatment. Patients were treated with 6 mg A1AT and BAL fluid was recovered 12 h later. Cathepsin B activity was significantly decreased when patients were treated with A1AT (fig 3A, p = 0.002). A1AT treatment also resulted in a statistically significant reduction in latent and active MMP-2 (fig 3B, p = 0.039 and 0.040, respectively). The band observed at 78 kDa is active MMP-9.

SLPI and lactoferrin levels in BAL fluid from patients with A1AT deficiency before and after A1AT treatment were examined by ELISA (fig 3C). Lactoferrin levels were significantly increased following A1AT treatment (p = 0.035), while SLPI levels were increased but not significantly (p = 0.286).

**DISCUSSION**

The pulmonary extracellular matrix is a constantly changing infrastructure comprised of a complex mixture of proteoglycans, collagen and elastin. It is estimated that as much as one-tenth of the extracellular matrix is degraded and replaced each day in the normal lung. Members of the serine, matrix metalloprotease and cysteinyl protease families have been associated traditionally with lung inflammation and airway extracellular matrix destruction. Cathepsin B is a cysteinyl protease that is expressed ubiquitously in lung tissue, particularly in bronchial epithelial cells and macrophages. Cathepsin B degrades types IV and X collagen and also fibronectin in vitro, and intratracheal instillation of cathepsin B has been shown to induce emphysema in hamsters. Cathepsin B activity is also increased in infective and inflammatory conditions such as pneumonia and cystic fibrosis. Schmidt et al found increased cathepsin B activity in BAL fluid from patients with both chronic bronchitis

and pneumonia. We have recently shown that cathepsin B activity in BAL fluid from patients with cystic fibrosis is increased several hundred fold compared with BAL fluid from healthy subjects.

A number of secretagogues of cathepsin B have been described. For example, interferon γ causes emphysema and alterations in the pulmonary protease/antiprotease balance when expressed in pulmonary tissues in mice by inducing

![Figure 1](image1.png)

**Figure 1** Cathepsin B and matrix metalloprotease 2 (MMP-2) activity in bronchoalveolar lavage (BAL) fluid from individuals with α1-antitrypsin deficiency (A1AT def) or pneumonia vs control subjects. (A) Cathepsin B activity in BAL fluid from control subjects, those with A1AT deficiency alone or in the presence of the specific cathepsin B inhibitor CA-074, and those with pneumonia. *p<0.001 when all experimental groups were compared. (B) Western blot analysis of cathepsin B in BAL fluid from control subjects (lanes 1, 3) and individuals with A1AT deficiency (lanes 2, 4). (C) MMP-2 activity was determined in BAL fluid from control subjects (cBAL), individuals with A1AT deficiency (a1BAL) and those with pneumonia (pBAL) using gelatin zymography. Bands at 72 and 66 kDa are representative of latent and active MMP-2, respectively, and are highlighted. Protein loading was corrected to albumin levels. Experiments or analyses of results were performed at least three times and representative data and SE are shown (upper limits).

![Figure 2](image2.png)

**Figure 2** Cathepsin B and matrix metalloprotease 2 (MMP-2) gene expression and activity from U937 macrophages exposed to pooled bronchoalveolar lavage (BAL) fluid from individuals with pneumonia (pBAL) containing free neutrophil elastase (NE). (A) RT-PCR of cathepsin B and MMP-2 were compared with glyceraldehyde 3-phosphate dehydrogenase (GAPDH) from cells stimulated with pBAL or pBAL and α1-antitrypsin (A1AT); *p = 0.006 (cathepsin B) and \( \uparrow p = 0.002 \) (MMP-2) when all experimental groups were compared. (B) Cathepsin activity 24 h after stimulation with pBAL or pBAL and A1AT; \( \uparrow p < 0.001 \) when all experimental groups were compared. (C) MMP-2 activity following stimulation with pBAL or pBAL and A1AT. Bands at 72 and 66 kDa are representative of latent MMP-2 and active MMP-2, respectively. Protein loading was corrected to albumin levels. Experiments were performed at least three times and representative data and SE are shown (upper limits).
Figure 3 Effects of α1-antitrypsin (A1AT) aerosolised augmentation therapy on protease and antiprotease levels in A1AT-deficient lungs. (A) Cathepsin B (Cat B) activity in bronchoalveolar lavage (BAL) fluid from patients with A1AT deficiency before and after treatment with 6 mg A1AT. Cathepsin B activity was corrected to albumin levels. *p = 0.002 pretreatment vs post-treatment samples. (B) Matrix metalloprotease 2 (MMP-2) activity was determined using gelatin zymography and by densitometry. Bands at 72 and 66 kDa are representative of latent MMP-2 and active MMP-2, respectively. The band observed at 78 kDa is MMP-2 activation latent and active forms, respectively (pretreatment vs post-treatment). The data are expressed as densitometry value ± SEM. Significant differences are indicated (pretreatment vs post-treatment). (C) Lactoferrin and secretory leucoprotease inhibitor (SLPI) levels in BAL fluid from patients with A1AT deficiency before and after treatment with 6 mg A1AT by ELISA. SLPI and lactoferrin levels were corrected to albumin levels; *p = 0.035 and †p = 0.286 (pretreatment vs post-treatment BAL fluid samples). Analyses of results were performed at least three times and representative data and SE are shown (upper limits).
severity of lung infections as well a reduction in inflammation. 24, 25 Lactoferrin and SLPI have key anti-inflammatory and antimicrobial roles. Lactoferrin has been shown to inhibit the lipopolysaccharide-induced expression and proteoglycan binding ability of IL-8 in human endothelial cells. 26 Lactoferrin can bind unmethylated CpG motifs, which are bacterial DNA products capable of stimulating various innate and acquired immune responses in human and murine models. 27 It is bactericidal against many of the common pathogens seen in the lung, is fungicidal and can prevent viral replication. 28–30 SLPI bactericidal against many of the common pathogens seen in the lung; role in protein processing and immunoregulation. 29-30

In this study, augmentation with A1AT resulted in increased levels of lactoferrin in BAL fluid from patients with A1AT deficiency. We speculate that aerosolised augmentation therapy resulted in decreased cathepsin cleavage of these key anti-inflammatory and antimicrobial proteins. Restoration of host innate immunity by abrogating cathepsin cleavage suggests a further potential therapeutic effect of aerosolised augmentation therapy.

The activities of multiple proteases in chronic lung disease are clearly deleterious to the host. We have elucidated a hierarchy in protease control and regulation whereby NE orchestrates tissue destruction and infection by activation of other proteases (cathepsin B and MMP-2). Neutralisation of the effects of NE with a specific antiprotease (A1AT) may be sufficient to lessen the overall protease burden in chronic lung infection disease without the need for inhibition of all proteases. This may not only prevent protease-induced lung destruction, but may play an important role in restoring lung host defence.

Funding: This work was supported by the Alpha One Foundation, Health Research Board of Ireland, the Program for Research in Third level Institutions administered by HEA, Science Foundation Ireland, Cystic Fibrosis Hope Source, Cystic Fibrosis Research Trust, Cystic Fibrosis Association of Ireland and the Royal College of Surgeons in Ireland.

Competing interests: None.

REFERENCES


